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Abstract
Despite having common overlapping immunophenotypic and morphological features, T-cell lymphoblastic leukemia
(T-ALL) and lymphoma (T-LBL) have distinct clinical manifestations, which may represent separate diseases. We
investigated and compared the epigenetic and genetic landscape of adult and pediatric T-ALL (n= 77) and T-LBL
(n= 15) patient samples by high-resolution genome-wide DNA methylation and Copy Number Variation (CNV)
BeadChip arrays. DNA methylation profiling identified the presence of CpG island methylator phenotype (CIMP)
subgroups within both pediatric and adult T-LBL and T-ALL. An epigenetic signature of 128 differentially methylated
CpG sites was identified, that clustered T-LBL and T-ALL separately. The most significant differentially methylated gene
loci included the SGCE/PEG10 shared promoter region, previously implicated in lymphoid malignancies. CNV analysis
confirmed overlapping recurrent aberrations between T-ALL and T-LBL, including 9p21.3 (CDKN2A/CDKN2B) deletions.
A significantly higher frequency of chromosome 13q14.2 deletions was identified in T-LBL samples (36% in T-LBL vs.
0% in T-ALL). This deletion, encompassing the RB1, MIR15A and MIR16-1 gene loci, has been reported as a recurrent
deletion in B-cell malignancies. Our study reveals epigenetic and genetic markers that can distinguish between T-LBL
and T-ALL, and deepen the understanding of the biology underlying the diverse disease localization.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell
lymphoblastic lymphoma (T-LBL) are precursor lym-
phoid neoplasms, characterized by the uncontrolled pro-
liferation of progenitor T-cells. A lymphoid neoplasm
with a bone marrow infiltration of malignant blast cells by
more than 20–25% is classified as T-ALL1. However, if the
bone marrow infiltration is less than 25% and the primary
disease localizes in the mediastinum, lymph nodes or the
extramedullary tissues, it is classified as T-LBL1. Despite
differences in clinical manifestation, T-ALL and T-LBL
have an overlapping immunophenotype and recurrent
genetic aberrations, such as NOTCH1 activating muta-
tions, CDKN2A/B deletions (cell cycle defects) and loss-
of-heterozygosity in chromosome 6q2,3. Previous stu-
dies4,5 have identified gene expression differences
between pediatric T-ALL and T-LBL, but no genetic or
epigenetic markers has yet been defined to distinguish
between the two malignancies, which are currently dif-
ferentiated solely based on bone marrow infiltration. DNA
methylation classification has been implicated as a prog-
nostic and diagnostic marker in various cancers including
hematological malignancies6–8. We have identified a CpG
island methylator phenotype (CIMP) panel, consisting of
1293 specific CpG sites, which classified pediatric T-ALL
patients into clinically relevant subgroups6,7. The CIMP−
(low methylation) T-ALL patient subgroup had a sig-
nificantly worse prognosis compared to the CIMP+ (high
methylation) subgroup6,7,9.
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The aim of this study was to further analyze DNA
methylation-based heterogeneity in T-cell lymphoblastic
malignancies, with focus on investigating if the previously
reported CIMP subgroups identified in pediatric T-ALL
were also present in T-LBL and adult T-ALL patients.
Furthermore, the methylomic and genomic landscape of
T-ALL and T-LBL were compared using high-resolution
genome-wide DNA methylation and copy number varia-
tion (CNV) detection arrays to investigate and identify
molecular markers that could distinguish between T-ALL
and T-LBL. Such epigenetic and genetic markers can give
an insight into the biological mechanisms underlying the
divergent clinical manifestation of the two neoplasms, as
well as reveal novel therapeutic targets and strategies.
Materials and methods
Patient samples
Bone marrow and fresh frozen lymph node tissue
samples from diagnostic (n= 76) and late relapsed (n= 1)
T-ALL and diagnostic (n= 15) T-LBL patients were
retrieved along with complete remission bone marrow
samples (n= 4). The adult (age > 18 years, n= 7) and
pediatric (age ≤ 18 years, n= 8) T-LBL patients, adult T-
ALL patients (age > 18 years, n= 12), were diagnosed at
University Hospital of Umeå, Sweden, between years 1998
and 2012. The study included all available T-ALL and T-
ALL samples diagnosed during the specified time period
and no further selection was done. The diagnosis was
based on morphologic, cytogenetic and immunopheno-
typic analysis, according to the WHO classification of
lymphoid neoplasms10. Patients were classified as T-ALL
or T-LBL based on blast cell infiltration in the bone
marrow, according to previously described guidelines1.
The 65 Nordic pediatric (age < 18 years) T-ALL patient
samples have been previously described and analyzed in
our lab by HumanMethylation450K arrays (data deposited
to the NCBI Gene Expression Omnibus (GEO) repository
accession no. GSE69954)6.
From the GEO repository, methylation profiles of nor-
mal immature (CD34+) and mature hematopoietic
(CD3+) cells (GSE49618)11, and normal bone marrow
(n= 7) and lymph node (n= 5) tissues (GSE50192)12,
were retrieved. Gene expression data of pediatric T-ALL
(n= 10) and T-LBL (n= 20) samples analyzed by Affy-
metrix HG-U133Plus2.0 GeneChip arrays were also
retrieved from GEO (GSE29986)5.
The study was approved by the Regional and/or
National Ethics Committees and the patients and/or their
guardians provided informed consent in accordance with
the Declaration of Helsinki.
DNA Extraction and bisulfite conversion
DNA extracted from freshly frozen lymph nodes and
bone marrow tissue samples were sodium bisulfite
converted using Zymo EZ DNA methylation kit (Zymo
Research, CA, USA) according to the manufacturer´s
protocol.
DNA Methylation array analysis, CIMP classification, and
epigenetic and mitotic age prediction
Illumina´s HumanMethylation450K BeadChip arrays
(Illumina Inc., San Diego, CA) were used for genome-
wide methylation profiling of bisulfite converted DNA.
These arrays interrogate 485,577 CpG sites across the
genome and the average beta (avg. β) methylation level of
each CpG site (CpGs) ranges from 0 (unmethylated) to 1
(fully methylated).
The raw methylation data was extracted using the
Genome Studio software (Illumina), and the data was
preprocessed, normalized and filtered, as described pre-
viously6 (Supplementary Fig. S1). The methylation data
were corrected for the bias introduced by different bead
types in the methylation array (BMIQ normalization)13,
and batch-effect corrected using ChAMP Bioconductor
package version 2.8.914 with default parameters.
CIMP classification by the 1293 CpGs CIMP panel was
carried out as previously described6. Briefly, patient
samples with >40% methylated CpGs (avg. β > 0.4) in the
CIMP panel were classified as CIMP high (CIMP+)
whereas patients with ≤40% methylated CpGs were clas-
sified as CIMP low (CIMP−).
DNA methylation-based models were used to predict
epigenetic and mitotic age15,16.
Differential methylation analysis
Differential methylation analysis of promoter-associated
CpGs i.e., CpG sites located up to 1500 base pair
upstream of genes, (n= 146035 CpGs) was performed
between T-ALL and T-LBL using ChAMP14 (Supple-
mentary Fig. S1). Batch effect corrected methylation data
were analyzed using default parameters and significant
differentially methylated CpGs (DM-CpGs) with adjusted
p-value < 0.05 and absolute delta beta ≥0.3 were retained
(Supplementary Fig. S1). Functional analysis was per-
formed using the functional annotation clustering tool in
Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.717. Clusters including more than
10 genes and with an enrichment score >1.0 were selected
as significant (Supplementary Table S1).
CNV analysis by DNA methylation arrays
The raw signal intensity data from the HumanMethy-
lation450K arrays was imported to R by the minfi pack-
age18 and CNV analysis was performed by the conumee
package19, where two T-ALL complete remission bone
marrow samples were used as reference. Parameters and
limits for deletion and gains were set for each individual
array through manual inspection. The CNV analysis
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included four complete remission samples as negative
controls in order to identify possible false positives due
to technical biases or germline variation. CNVs identi-
fied by the segmentation with fewer than 10 observa-
tions, as defined by the conumee package, were excluded
from the analysis. CNV segments overlapping in three
or more samples in either T-ALL or T-LBL and in fewer
than three of the four negative controls were summar-
ized with the minimal common region. One of the
samples was excluded as the limits could not be set with
any certainty due to high variation. Group comparisons
of CNVs were performed using Fisher’s exact test on
individual CNVs. Human genome GRCh37 (NCBI)/
hg19 (UCSC) was used for assigning all chromosome
positions.
CNV analysis by genome-wide SNP array
Genome-wide copy number variation (CNV) analysis
was performed using whole-genome single-nucleotide
polymorphism (SNP) Infinium CytoSNP-850K v1.1
BeadChip microarrays (Illumina), covering approximately
850 000 SNPs. In accordance with the manufacturers’
protocol, 200 ng DNA was hybridized on a beadchip after
whole-genome amplification, after which the arrays were
scanned using the HiScan instrument (Illumina). Geno-
typing results were visualized, normalized and clustered
using Genotyping module of the GenomeStudio software
(Illumina). The cnvPartition 3.2.0 (Illumina) was applied
for CNV detection by retrieving Log R Ratio (LRR, the
ratio between the observed and the expected probe
intensity) and the B Allele Frequency (BAF). Deviations
from the expected values indicate copy number altera-
tions. Human genome GRCh37 (NCBI)/hg19 (UCSC) was
used for assigning all chromosome positions.
Bioinformatic and statistical analysis
Principal component analysis (PCA) of centrally scaled
DNA methylation (avg. β values) and log2 scaled gene
expression (average signal values) data was carried out
using SIMCA version 14 (Umetrics, Umeå, Sweden). For
statistical analysis, the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL) software version 24 was
used along with R.
Statistical tests included Fisher´s exact test for com-
paring categorical variables and independent samples T-
test for comparing continuous variables. Welch´s two
sample T-test was used to compare log2 transformed gene
expression data. Cluster analyses were performed using
Wards method with Euclidean distance metric.
Results
Demographic data
A total of 15 T-LBL (7 adult and 8 pediatric), 77 T-ALL
(12 adult and 65 pediatric) patient samples, and four
complete remission samples were analyzed using DNA
methylation arrays. Publicly available DNA methylation
array data of normal bone marrow and lymph node
samples12, as well as sorted CD3+ and CD34+ cells11
were further included as reference samples. There were
no significant differences in age and gender distribution
between T-ALL and T-LBL patients, and both malig-
nancies showed higher prevalence in males (Table 1).
The T-ALL and T-LBL patient samples were CIMP
classified according to the previously defined CIMP panel,
consisting of 1293 CpGs6. Irrespective of disease (T-ALL
vs. T-LBL) and age group, the frequency of CIMP+ was
similar (61.5–71.4%) (Table 1).
Genome-wide DNA methylation profiling
Genome-wide DNA methylation patterns across adult
and pediatric T-ALL and T-LBL patient samples along
with reference samples were explored by principal com-
ponent analysis (PCA) analysis on batch-effect corrected
DNA methylation array data (Fig. 1, Supplementary Fig.
S2). The PCA plots were generated using center scaled
beta (avg. β) values of the genome-wide CpGs retained
after filtering (n= 397316), comprising of 76% gene-
related and 24% intergenic CpGs. The PCA did not pro-
ject T-ALL and T-LBL as separate clusters, nor on
patients’ age group in the first and second principal
components (Fig. 1). However, the non-malignant refer-
ence samples (bone marrow and lymph node origin)
Table 1 Demographic data of T-ALL and T-LBL study cohort.
T-ALL T-LBL T-ALL vs. T-LBL (adult/pediatric) p-values
Adult Pediatric Adult Pediatric
No. of samples 12 65 7 8 –
Male/female (% male) 8/4 (66.7%) 43/22 (66.2%) 5/2 (71.4%) 7/1 (87.5%) 1/0.42a
Age, years (median, range) 35 (21–65) 7 (1–17) 33 (19–77) 10.5 (3–18) 0.91/0.34b
CIMP status, +/− (% CIMP+) 8/4 (66.7%) 40/25 (61.5%) 5/2 (71.4%) 5/3 (62.5%) 1/1a
aFisher´s exact test, bIndependent samples T-test.
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clustered separately from the T-ALL and T-LBL samples,
reaffirming large methylomic variation between normal
and malignant tissues. Notably, CIMP status separated the
malignant samples into CIMP+ enriched cluster and
CIMP− enriched cluster. This shows the presence of
CIMP subgroups in both T-ALL and T-LBL (Fig. 1).
Similar clustering was observed upon performing PCA
using only promoter-associated CpG sites (Supplemen-
tary Fig. S2).
CIMP subgroups have differential predicted cellular age
Adult T-ALL samples and pediatric/adult T-LBL sam-
ples were CIMP classified based on the CIMP panel




















Fig. 1 Principal component analysis (PCA) of global DNA methylation. PCA scoring plots based on the average β values of 397 316 CpGs. The
samples in the PCA plots are colored by (a) sample type: T-ALL (n= 77), T-LBL (n= 15), and non-malignant lymph node (n= 5) and bone marrow
(N= 11) reference tissue, (b) Age group: pediatric (n= 73) and adult (n= 19) and (c) CIMP status (59 CIMP+ and 33 CIMP−).
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the presence of CIMP subgroups in all age groups of T-
LBL and T-ALL (Fig. 2a).
The CIMP subgroups in T-LBL and adult T-ALL had
similar characteristics as the CIMP subgroups in pediatric
T-ALL9 (Fig. 2a). The methylation profile of the CIMP−
malignant samples were closer to the CIMP profile of the
normal reference samples (complete remission samples
and normal sorted CD34+ and CD3+ T-cells), whereas
the CIMP+ samples were more hypermethylated com-
pared to the reference samples (Fig. 2a).
The CIMP subgroups in pediatric T-ALL have been
previously shown to have differential replicative histories9,
reflected by significant differences in predicted epigenetic
and mitotic age9,15,16. Similar differences in epigenetic age
and mitotic age were shown in the CIMP subgroups
within T-LBL and adult T-ALL, with the CIMP+ samples
having an older predicted epigenetic15 and mitotic age16
(Fig. 2b).
Differential DNA methylation analysis between T-ALL and
T-LBL
Despite the overlapping global DNA methylation pat-
terns, T-ALL and T-LBL have different patterns of disease
distribution and clinical manifestation. In order to
investigate methylomic differences between T-ALL and
T-LBL, differential methylation analysis was performed
using the ChAMP algorithm focusing on promoter-
associated CpG sites (n= 146,035). To avoid identifying
age-related DNA methylation differences, differential
methylation analysis was carried out firstly, between all T-
ALL (n= 77) and T-LBL (n= 15) samples, secondly,
between adult T-ALL (n= 12) and adult T-LBL (n= 7)
and lastly, between pediatric T-ALL (n= 65) and pediatric
T-LBL (n= 8) (Supplementary Fig. S1, Supplementary
Table S2). A total of 634 differentially methylated CpGs
(DM-CpGs), with an adjusted p-value < 0.05 and absolute
delta β (absΔβ) value ≥ 0.3, were common between all
three analyses (Fig. 3a–b).
Hierarchical clustering separated the 634 DM-CpGs
and analysis was focused on the two clusters (cluster 2
and 4) that were not associated with CIMP class (Fig. 3b,
Supplementary Fig. S3). Cluster 2, consisting of 24 DM-
CpGs hypermethylated in T-LBL and cluster 4, with 104
DM-CpGs hypomethylated in T-LBL were identified as
DM-CpGs with the most variable methylation profile























































Fig. 2 Validation of CIMP subgroups in T-ALL and T-LBL. a The heat map shows average β values of 1293 CpGs (as rows) in the CIMP panel of T-
ALL and T-LBL samples along with reference samples including tumor-free bone marrow remission samples (n= 4) and sorted CD34+ (n= 3) and
CD3+ (n= 3) cells. The samples (columns) are sorted according to increasing CIMP methylation percentage. b Epigenetic and mitotic age, predicted
using Horvath and Yang et al. models15,16, compared between CIMP subgroups in T-ALL and T-LBL.







































Fig. 3 Differential DNA methylation analysis between T-ALL and T-LBL. a Venn diagram showing the common, overlapping 634 DM-CpGs
between T-ALL and T-LBL. b Heat map of avg.β values of the 634 DM-CpGs in T-ALL, T-LBL and non-malignant reference samples. The hierarchical
cluster analysis of the DM-CpGs generated four clusters of CpG sites which are marked on the right. c Heat map showing 128 DM-CpGs from cluster 2
and 4 (from Fig. 3b), that represent methylomic differences between T-ALL and T-LBL, independent of CIMP profiles. d PCA of the 128 DM-CpGs
showing the separation of T-ALL and T-LBL samples, based on tissue type, age group and CIMP status.
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with CIMP profiles (Fig. 3c, Supplementary Fig. S3). PCA
using avg. β values of the 128 DM-CpGs (from clusters 2
and 4) clearly separated T-ALL and T-LBL samples,
without discriminating between different patient age
groups or the CIMP phenotype (Fig. 3d). Furthermore,
the methylation signature of the 128 DM-CpGs did not
separate the non-malignant lymph nodes and bone mar-
row reference samples, showing that the DM-CpGs did
not represent tissue-specific methylation differences
between T-ALL and T-LBL (Fig. 3d).
Functional relevance of DM-CpGs between T-ALL and T-
LBL evaluated by integrated gene expression analysis
The potential functional relevance of the 128 DM-CpGs
was evaluated by retrieving publicly available gene
expression array data of T-ALL (n= 10) and T-LBL (n=
20)5. The public gene expression data5 was used to eval-
uate whether the transcriptomic profile of the genes,
corresponding to the identified 128 DM-CpGs, also dis-
tinguished between T-ALL and T-LBL. The 128 DM-
CpGs mapped to a total of 110 unique genes out of which
gene expression data were available for 100 genes (219
gene expression probes) in 10 T-ALL and 20 T-LBL
pediatric patients5. PCA of the log2-transformed average
signal values of 219 gene expression probes clustered T-
ALL and T-LBL samples separately (Fig. 4a). This showed
that the differentially methylated CpG loci identified in
our cohort of T-ALL and T-LBL patients, also separated
the two diseases based on the corresponding gene
expression profile in a separate cohort of T-ALL and T-
LBL patients5 (Fig. 4a). Gene enrichment analysis of these
110 genes, revealed significant enrichment of transmem-
brane and membrane-associated proteins (Supplementary
Table S1).
An integrated DNA methylation and gene expression
analysis using Basso´s cohort was performed for the top
ten most significant DM-CpGs (Supplementary Table S3).
Amongst the top most significant DM-CpGs, two sites
hypomethylated in T-LBL compared to T-ALL, mapped
to the shared promoter region of SGCE and PEG10 genes
(Fig. 4b, Supplementary Table S3). The expression of the
SGCE and PEG10 genes was significantly differentially
expressed in Basso's cohort (SGCE log2FC 3.98, p < 0.001
and PEG10 log2FC 1.87, p < 0.001) with a higher gene
expression in T-LBL than in T-ALL (Fig. 4c, Supple-
mentary Table S3).
Copy number variation analysis identified a higher
frequency of Ch13q14.2 deletions in T-LBL
To explore and compare the genomic landscape of T-
ALL and T-LBL, we screened for recurrent deletions or
gains in patient samples using the HumanMethyla-
tion450K arrays. A total of 17 chromosomal regions were
identified with recurrent copy number variations out of
which, a majority were common in both T-ALL and T-
LBL patients (Fig. 5a, Table 2). Deletion in the CDKN2A/
2B locus (9p21.3), a known recurrent deletion in T-ALL
and T-LBL, was detected in 10% of T-ALL and 14% of T-
LBL in our cohort (Table 2).
However, two CNVs, namely gain of 5p13.1-p15.33 (1
vs. 21%, p= 0.013) and deletion of 13q13.13-q14.3 (0 vs.
36%, p < 0.001), were significantly overrepresented in T-
LBL samples as compared with T-ALL samples (Fig. 5a-b,
Table 2). Focused analysis of the 13q14.13-q14.3 region
identified 13q14.2 as the minor common genomic dele-
tion region in the five T-LBL patients positive for the
deletion. This region encompassed the tumor suppressor
gene RB1, microRNA genes MIR15A and MIR16-1, as
well as the DLEU1 gene (Fig. 5c).
In order to validate the 13q14.2 deletions and gains in
chromosome 5 in T-LBL, all fifteen T-LBL samples were
further analyzed by CytoSNP-850K arrays (Table 3, Sup-
plementary Table S4). SNP array analysis verified the gain
of all or parts of chromosome 5 in three (21%) of the T-
LBL samples (Supplementary Table S4). The recurrent
13q14.2 deletions in five (36%) of the T-LBL samples were
also confirmed by SNP-array analysis (Table 3, Fig. 5c).
Discussion
The biology behind the different clinical manifestation
in T-ALL and T-LBL is still not well established. Despite
overlapping immunophenotypic and morphological fea-
tures, T-ALL and T-LBL have divergent clinical mani-
festation, with lymph nodes/extramedullary tissue
infiltration associated with T-LBL and a predominant
bone marrow infiltration in T-ALL. By high-resolution
genome-wide DNA methylation and copy number varia-
tion detection arrays, we aimed at exploring the methy-
lomic and genomic landscape in T-ALL and T-LBL to
identify molecular markers that could differentiate
between the two diseases and could also help evaluate the
biology behind the differential pattern of primary disease
distribution. Neither global, nor genome-wide promoter-
focused DNA methylation analysis by PCA, could sepa-
rate T-ALL patients from T-LBL patients or distinguish
between adult and pediatric patients. It has been shown
previously that adult and pediatric T-ALL have significant
overlap of leukemia-specific genetic and cytogenetic
lesions20,21. It can therefore be speculated that adult and
pediatric cases also have similar methylation profiles, as
demonstrated by the co-clustering of adult and pediatric
patients in our multivariate analysis. The largest variation
in global and promoter-associated DNA methylation
pattern between the patient samples was based on CIMP
status, verifying the presence of epigenetic CIMP sub-
groups in a broader set of T-cell malignancies including
pediatric and adult T-LBL and adult T-ALL patients,
which has not been shown before6,7,9. Even though the


















































Fig. 4 Integrated methylation and expression analysis of differentially methylated CpG sites between T-ALL and T-LBL. a PCA scoring plot
showing separate clustering of Basso´s cohort of pediatric T-ALL (n= 10) and T-LBL (n= 20) samples based on log transformed average signal of 100
(219 probes) out of 110 unique genes corresponding to the 128 DM-CpGs. The gene expression data of T-ALL and T-LBL samples, analyzed by HG-
U133Plus2.0 GeneChip arrays, was retrieved from the public data repository (GSE29986) (Basso, Mussolin et al. 2011). b Mean methylation levels at
single CpG site resolution in PEG10 (+sense strand) and SGCE (-antisense strand) promoter regions are compared between T-ALL (gray), T-LBL
(yellow) and non-malignant lymph node (cyan) and bone marrow (blue) reference samples. The significant differentially methylated CpG sites are
marked and the 95% confidence interval, based on the T distribution, is represented by dashed lines while the mean avg. β is represented as a solid
line. c Boxplots comparing the gene expression of neighboring SGCE and PEG10 genes in T-ALL (n= 10) and T-LBL (n= 20) patient cohort (Basso,
Mussolin et al. 2011). The p-value is determined by Welch´s two sample T-test.
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Fig. 5 CNV analysis by HumanMethylation450K and CytoSNP-850K arrays. a Heat map showing copy number variations (deletions and gains) in T-
ALL (n= 77) and T-LBL (n= 15) patients samples analyzed by HumanMethylation450K arrays. Samples are sorted as T-ALL and T-LBL and with increasing
CIMP methylation percentage within the diagnoses. b–c Chromosome 13q14.2 deletions in 5 T-LBL patients analyzed by HumanMethylation450K arrays (b)
and by Infinium CytoSNP-850K arrays (c). Interesting genes mapped within the minimal common region 13q14.2 are labeled.
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prognostic significance of CIMP profiling in T-LBL and
adult T-ALL could not be validated because of limited
cohort size, the CIMP subgroups in aforementioned
diagnoses showed similar differences in cellular pro-
liferative history, as shown previously by us in pediatric T-
ALL CIMP subgroups9. The CIMP+ T-LBL and adult T-
ALL patients had older predicted epigenetic and mitotic
age compared to the CIMP− patients, which is in line
with our previously published data9.
In order to identify specific genomic loci with differ-
ential DNA methylation between T-ALL and T-LBL, we
performed differential methylation analysis in the
promoter-associated CpG sites, considering the functional
relevance of DNA methylation in promoters. A set of 128
DM-CpG sites was identified, that separated T-ALL and
T-LBL as distinct clusters, without reflecting methylomic
variations based on tissue type, age, or CIMP hetero-
geneity. Functional analysis of genes corresponding to the
128 DM-CpGs between T-ALL and T-LBL revealed an
overrepresentation of membrane and transmembrane
associated proteins. Gene expression signatures, dis-
criminating T-ALL and T-LBL identified in previous
studies, were also shown enriched in genes encoding
cellular adhesion proteins and extracellular matrix pro-
teins4,5. This implies that T-ALL and T-LBL have biolo-
gical differences that might govern the difference in their
different disease manifestation. The most significant dif-
ferentially methylated sites mapped to the shared CpG-
island rich promoter region of Sarcoglycan-epsilon
(SGCE) and its neighbor, paternally expressed gene 10
(PEG10), which are both maternally imprinted genes on
chromosome 7q2122. PEG10 plays a vital role in placental
formation and differentiation of adipocytes while SGCE
gene encodes a transmembrane protein that links the
actin cytoskeleton to extracellular matrix23. However,
deregulated PEG10 expression is associated with malig-
nant transformation, affecting cell proliferation and
apoptosis24. Both PEG10 and SGCE are known to be
overexpressed in high-risk B-cell chronic lymphocytic
leukemia (B-CLL), with promoter DNA methylation reg-
ulating the gene expression24. Overexpression of PEG10
has also been implicated in progression of various solid
cancers including hepatocellular carcinoma25, pancreatic
cancer26, breast cancer27 and prostate cancer24. Over-
expression of PEG10 in these solid tumors was shown to
correlate with higher TNM stage and lymph node
metastasis28. Interestingly, long non-coding RNA PEG10,
also encoded from 7q21, was shown upregulated in diffuse
large B cell lymphoma (DLBCL), which correlated with
worse prognosis29. One of the oncogenic effects of PEG10
in the solid cancers has been shown to promote meta-
static migration and promoting epithelial-mesenchymal
transition of neoplastic cells24. The overlapping epigenetic
and transcriptomic disparities identified between T-ALL
and T-LBL in our study might contribute to the different
manifestations of the malignancies. However the func-
tional relevance has to be further evaluated in order to
conclude the epigenetic contribution to disease
distribution.
Furthermore, we explored possible similarities and dif-
ferences in genetic alterations between T-LBL and T-ALL.
The most frequently commonly observed CNVs in T-ALL
Table 2 Copy number variation (CNV) analysis by HumanMeth450K arrays.











1 6,050,001 7,300,000 1p36.23-p36.31 Deletion 3 1 4 7 0.516
4 153,900 001 154,600 000 4q31.3 Deletion 4 0 5 0 1.000
5 10,001 40,650 000 5p13.1-p15.33 Gain 1 3 1 21 0.013*
5 100,250 001 106,300 000 5q21.1-q21.3 Deletion 3 1 4 7 0.516
5 170,750 001 180,905 260 5q35.1-q35.3 Deletion 4 1 5 7 1.000
6 80,250 001 88,400 000 6q14.1-q15 Deletion 11 0 14 0 0.201
7 148,850 001 153,550 000 7q36.1-q36.2 Deletion 3 1 4 7 0.516
8 40,800 001 43,838 887 8p11.1-p11.21 Gain 7 0 9 0 0.594
8 129,550 001 136,800 000 8q24.21-q24.23 Gain 8 1 10 7 1.000
9 21,400 001 23,850 000 9p21.3 Deletion 8 2 10 14 0.664
11 105,850 001 108,450 000 11q22.3 Deletion 4 2 5 14 0.252
12 12,500 001 14,100 000 12p13.1-p13.2 Deletion 6 1 8 7 1.000
13 46,950 001 51,500 000 13q14.13-q14.3 Deletion 0 5 0 36 <0.001*
13 84,450 001 115,109 878 13q31.1-q34 Gain 4 0 5 0 1.000
19 60,001 24,631 782 19p11-p13.3 Gain 3 1 4 7 0.516
19 48,500 001 59,118 983 19q13.33-q13.43 Gain 4 1 5 7 1.000
21 35,400 001 48,119 895 21q22.11-q22.3 Gain 4 0 5 0 1.000
aFisher's exact test, *p-value < 0.05.
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and T-LBL was the deletion of 9p21.3 including the
CDKN2A/2B loci. Previous studies have also identified
9p21.3 deletions commonly recurrent in both T-ALL and
T-LBL2,30–32.
Interestingly, we identified and validated a frequently
deleted genomic region on chromosome 13q14.2 present
in 36% (5/14) of the T-LBL samples, that was not
observed in any T-ALL sample (0/77). Similarly, gain of all
or parts of chromosome 5 were observed in T-LBL
patients in our study cohort. Trisomy 5, gain of the whole
chromosome 5, is recurrent in hematological malignant
cases with hyperdiploid karyotype (chromosome number
>50). Our findings are in line with a previous study that
reported hyperdiploid karyotype significantly more fre-
quent in T-LBL compared to T-ALL patients33.
The presence of 13q14.2 deletions in T-LBL samples has
also been described in a previous study that reported
13q14.2 deletions in 2 out of 12 T-LBL (17%)31. However,
that study also observed 13q14.2 deletions in 6 out of 57
(11%) T-ALL patients, which were not seen in our Nordic
T-ALL cohort31. The 13q14.2 region partially overlaps with
the most commonly deleted region in B-cell chronic
lymphocytic leukemia (B-CLL)34–36 and contains RB1,
KCNRG, TRIM13, DLEU1/2, MIR16-1, and MIR15A genes.
In addition, 13q14 deletions have been observed in other
hematological malignancies including mantle cell leukemia,
multiple myeloma and acute myeloid leukemia37–40. One of
the downstream inhibitory targets ofMIR16-1 and MIR15A
include the anti-apoptotic BCL2 gene. In B-CLL, loss of
13q14.2 region has been shown associated with reduced
MIR16-1 and MIR15A expression and increased BCL2
mRNA levels41. Another study showed through Zebrafish
modeling, that increased expression of BCL2 favored the
development of T-LBL over T-ALL42. However, further
functional analyses are required to elucidate the link
between 13q14.2 deletions, BCL2 overexpression and T-
LBL biology. If 13q14.2 deletions and subsequent BCL2
overexpression are validated as potential oncogenic events
in T-LBL, the next step would be to evaluate the efficacy of
drugs like Venetoclax, for treating 13q14.2 deleted T-LBL
patients. Venetoclax, a selective inhibitor of BCL2, is cur-
rently used as a targeted therapy for treating CLL43 and
acute myeloid leukemia44, but its efficacy in treating T-
LBL patients is yet to be determined.
Table 3 Verification of CNV analysis by CytoSNP-850K v1.1 arrays.
CNV Ch 13q14.2 analysis
Sample ID HumMeth450K array CytoSNP-850K v1.1 array
Start End Deletion (yes/no) Start End Deletion (yes/no) Genotype
T-LBL 1 38,900,001 54,850,000 Yes 40,021,077 46,802,657 Yes Heterozygous
T-LBL 2 40,250,001 56,200,000 Yes 40,363,878 59,634,447 Yes Heterozygous
48,902,121 50,698,153 Yes Homozygous
T-LBL 3 46,950,001 88,350,000 Yes 46,893,680 88,924,926 Yes Heterozygous
48,985,639 49,072,565 Yes Homozygous
84,559,815 84,705,359 Yes Homozygous
T-LBL 4a – – NA – – No –
T-LBL 5 – – No – – No –
T-LBL 6 – – No – – No –
T-LBL 7 30,400,001 51,500,000 Yes 29,499,142 51,21,608 Yes Heterozygous
T-LBL 8 31,800,001 60,000,000 Yes 31,926,477 58,586,236 Yes Heterozygous
T-LBL 9 – – No – – No –
T-LBL 10 – – No – – No –
T-LBL 11 – – No – – No –
T-LBL 12 – – No – – No –
T-LBL 13 – – No – – No –
T-LBL 14 – – No – – No –
T-LBL 15 – – No – – No –
aNA-inconclusive data.
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In conclusion, we showed that DNA methylation CIMP
subgroups, with prognostic significance in pediatric T-
ALL, are also present in adult T-ALL, as well as in
pediatric and adult T-LBL, suggesting a broader relevance
of CIMP classification in T-cell malignancies. Further-
more, epigenetic and genetic profiling revealed molecular
differences between T-ALL and T-LBL, which may con-
tribute to the differential biology of the two neoplasms.
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